Mylan and Biocon Launch Ogivri (biosimilar, trastuzumab) in Australia

 Mylan and Biocon Launch Ogivri (biosimilar, trastuzumab) in Australia

Mylan and Biocon Launch Ogivri (biosimilar, trastuzumab) in Australia

Shots:

  • Ogivri is the first biosimilar to Herceptin (trastuzumab) to be approved and launched in Australia for the treatment of HER2-overexpressing breast cancer and metastatic stomach cancer and will be available on the Pharmaceutical Benefits Scheme
  • The TGA’s approval of Ogivri is based on data which demonstrated bio-similarity to Herceptin with no clinically meaningful differences in efficacy, safety, purity and potency. The HERITAGE study resulted in bio-similarity in terms of reduction in tumor size @24 wks. & OS @48 wks.
  •  Ogivri is a biosimilar of Roche’s Herceptin and has received FDA’s approval in Dec’2017 for HER2-overexpressing breast or metastatic stomach cancer (gastric or gastroesophageal junction adenocarcinoma

Click here to­ read full press release/ article | Ref: Biocon | Image: Patch

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post